Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
First of its kind screening for Glaucoma at grass root level over 10k screened already
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
Subscribe To Our Newsletter & Stay Updated